• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

An Agile Rebound on the Horizon

This recent laggard looks set for a turnaround, making it a good value at current levels.
By DAVID KATZ Apr 01, 2013 | 03:00 PM EDT
Stocks quotes in this article: A, TMO

There are several companies we've been watching, but we have yet to pull the trigger on them. One such name is Agilent Technologies (A).

Agilent made an interesting case for itself at its recent investor day meeting. Yes, the stock lagged through 2012 and has continued that trend year to date, with slowing growth last year and flattish performance so far in 2013. But, long-term, the market for its products and the company's positioning in the industry promise better days ahead.

For some background, Agilent was the instruments business at the core of Hewlett-Packard (HPQ), and was spun out in 1999. The company sells instruments and related supplies and services in four segments: life sciences, chemical analysis, electronic measurement and diagnostics/genomics. The last division was forged through the $2.2 billion acquisition of Dako last June, the biggest deal the company has inked to date.

In general the instruments business is a good one. It's a segment driven by increased innovation in end customers such as universities, pharmaceutical and biotech companies, hardware developers and chemical producers. Instruments constitute a capital-spending decision, and demand for Agilent's products slowed in 2012 along with the global economy.

There is a lock-in effect from a large installed base, in part for consumables but also due to customers' comfort and experience with a specific company's product operation and reliability. Operating margin here is high and stable in the 20% range.

That said, the current fiscal year (ending October) is shaping up be Agilent's second consecutive poor year for organic growth, mainly but not solely due to the tough macroeconomic environment. Its business and geographic mix have not been kind to Agilent in this cycle, and it has lost market share as a result. But the company is committed to outgrowing its markets in fiscal 2014, and this should work in part due to easy comparisons and the nascent global recovery. In addition, Agilent has put in efforts to fix its loss-making MRI/NMR business and to boost gross margin by cutting related costs. These will all assist in operating margin by perhaps 250 basis points over the next three years.

Management seems to be somewhat more cognizant of shareholders than it had previously been, as well. It boosted the paltry dividend by 20%, and the yield now stands at 1.2%. The acquisition of Dako, a strategic plus, was funded completely by offshore cash -- an intelligent approach. Further, the company has aggressively expanded its share-repurchase program, having targeted buybacks of $500 million this year.
Overall, the company generates well over $1 billion annually in free cash flow. That gives it the flexibility to make thoughtful acquisitions, and it also allows compensation of shareholders.

Agilent shares trade at around 14x this fiscal year's earnings estimate, which is interesting for a company for which forward earnings growth can be in the 10%-per-annum range for the next couple of years. Its balance sheet is strong enough to comfortably support its business, and management is using the low-interest-rate environment to optimize its debt structure. Our assessment of fair value is in the low-$50s range.

We think Agilent is a reasonable, though not table-pounding, investment at the current level. It would become even more compelling in the high $30s. In the past we have recommended and still prefer Thermo Fisher (TMO), a similar operation that has performed better and more consistently over the last few years, and is valued at a slightly more attractive level. Thermo's business and geographic mix is also better, with a larger proportion of high-margin consumables. We like the instrument industry and believe it's an attractive and timely investment space.

That said, we believe both stocks should do well from here. Bottom line: For those seeking recent laggards with favorable longer-term outlooks, Agilent should be of interest.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Katz and his Matrix Asset Advisors were long TMO.

TAGS: Investing | U.S. Equity

More from Investing

On Surface Market Appeared Quiet, but Underneath Fireworks Sparked

James "Rev Shark" DePorre
Aug 16, 2022 4:37 PM EDT

Short-squeezes, stock rotations and parabolic S&P moves rocked the day.

You Bet Your BP I'd Be a Buyer

Mark Sebastian
Aug 16, 2022 2:32 PM EDT

With oil down over the last two days, BP's stock has held up.

Doug Kass: We May Now Be Approaching Another Important Top in the Market

Doug Kass
Aug 16, 2022 1:30 PM EDT

To justify buying at today's prices means that one expects a new Bull Market leg - something I remain dubious of.

Cisco, Long a Steady Tech Stock, Is Under the Microscope Ahead of Earnings

Brad Ginesin
Aug 16, 2022 12:45 PM EDT

Some top analysts are flashing a yellow light on the network equipment maker ahead of its quarterly report and amid tightening competition. But is caution really warranted for long-term investors?

2 Big-Name, Single-Stock ETFs With a Foreign Twist Could Be on the Horizon

Mark Abssy
Aug 16, 2022 12:00 PM EDT

The potential offerings from Roundhill aren't geared solely to the retail investor but also could interest smaller institutions and other ETF issuers.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login